WILLIAM E. ROTE - 11 May 2022 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
Senior Vice President, R&D
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
11 May 2022
Net transactions value
-$33,940
Form type
4
Filing time
12 May 2022, 20:49:57 UTC
Previous filing
02 Feb 2022
Next filing
26 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Sale $16,448 -750 -1.7% $21.93 44,485 11 May 2022 Direct F1
transaction TVTX Common Stock Sale $17,493 -813 -1.8% $21.52 43,672 11 May 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.